Fulltext

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study

Hss AS 1 , Koh MT , Tan KK , Chan LG , Zhou L , Bouckenooghe A Show all authors , Crevat D , Hutagalung Y

Affiliations 

  • 1 Department of Pediatrics, Hospital Raja Permaisuri Bainun, Jalan Hospital, Ipoh, Perak, Malaysia. Electronic address: amarhss@gmail.com
Vaccine, 2013 Dec 2;31(49):5814-21.
PMID: 24135573 DOI: 10.1016/j.vaccine.2013.10.013

Abstract

Dengue disease is a major public health problem across the Asia-Pacific region for which there is no licensed vaccine or treatment. We evaluated the safety and immunogenicity of Phase III lots of a candidate vaccine (CYD-TDV) in children in Malaysia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications